+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Integrin Beta 3"

Integrin Beta 3 Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type - Product Thumbnail Image

Integrin Beta 3 Global Market Insights 2023, Analysis and Forecast to 2028, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • October 2023
  • 85 Pages
  • Global
From
Cells Expressing Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Cells Expressing Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 36 Pages
  • Global
From
Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players - Product Thumbnail Image

Integrin Beta 3 Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players

  • Report
  • May 2022
  • 57 Pages
  • Global
From
  • 3 Results (Page 1 of 1)
Loading Indicator

Integrin Beta 3 is a protein found on the surface of cells that plays a role in the development of leukemia. It is a target for drug development, as it is involved in the growth and spread of cancer cells. Inhibiting Integrin Beta 3 can help to reduce the growth of cancer cells, and therefore can be used as a treatment for leukemia. Several companies are researching and developing drugs that target Integrin Beta 3. These include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are working to develop drugs that can target Integrin Beta 3 and potentially be used to treat leukemia. Show Less Read more